"The Company also has greater China rights to ZEVALIN® (Ibritumomab Tiuxetan) and MARQIBO® (vincristine sulfate LIPOSOME injection), each of which is approved in the United States by the FDA for specified indications. Due to the evolving standard of care environment, the rare and niche indication for these products, and the Company’s commitment to prioritize resources, the Company is currently evaluating its options for these products."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.